Development of a cytokine-modified allogeneic whole cell pancreatic cancer vaccine.
The management of patients with pancreatic cancer is a multidisciplinary approach that presents enormous challenges to the clinician. Overall 5-yr survival for all patients remains < 3%. Symptoms of early pancreas cancer are nonspecific. As such, only a fraction of patients are candidates for surgery. While surgical resection provides the only curative option, most patients will develop tumor recurrence and die of their disease. To date, the clinical benefits of chemotherapy and radiation therapy have been important but have led to modest improvements. Tumor vaccines have the potential to specifically target the needle of pancreas cancer cells amidst the haystack of normal tissue. The discovery of pancreas tumor-specific antigens and the subsequent ability to harness this technology has become an area of intense interest for tumor immunologists and clinicians alike. Without knowledge of specific antigen targets, the whole tumor cell represents the best source of immunizing antigens. This chapter will focus on the development of whole tumor cell vaccine strategies for pancreas cancer.
Laheru
Dan
D
The Sidney Kimmel Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Biedrzycki
Barbara
B
Thomas
Amy M
AM
Jaffee
Elizabeth M
EM
D000951:Antigens, Neoplasm / Q000276:immunology; D019496:Cancer Vaccines; D016207:Cytokines / Q000276:immunology*; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D010190:Pancreatic Neoplasms / Q000276:immunology* / Q000401:mortality / Q000601:surgery; D016019:Survival Analysis
D000951:Antigens, Neoplasm; D019496:Cancer Vaccines; D016207:Cytokines